MUK five study: key findings and clinical implications

The MUK five phase II trial compared the activity and safety of carfilzomib versus bortezomib in triplet combination with cyclophosphamide and dexamethasone for patients at first relapse, or refractory to first-line treatment. Professor Kwee Yong summarises the most recent findings of the study which were presented at ASH 2018.

The views expressed in this video are those of the speaker.

UK/NP/1806/0035(1)u - February 2019

You are now leaving the Myeloma Hub

This link opens another website that is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Please confirm you wish to continue.